D-Sight

Executive Summary

D-Sight is a Spanish medtech company specializing in AI-powered diagnostic solutions for ophthalmology, focusing on early detection and monitoring of retinal diseases like diabetic retinopathy and age-related macular degeneration. Founded in 2020 and based in Barcelona, the company leverages machine learning to analyze retinal imaging, aiming to improve screening accuracy and efficiency in clinical settings. With a commercial-stage product and a lean team of 1-50 employees, D-Sight addresses a significant unmet need in vision care, where early intervention can prevent irreversible blindness. The global prevalence of diabetes and aging populations drives demand for scalable, automated screening tools, positioning D-Sight's platform as a potential standard-of-care adjunct. The company operates in a competitive landscape but differentiates through its focus on disease progression analysis and integration with existing workflows. While financial details remain undisclosed, D-Sight's progress to commercial stage suggests initial market validation, likely through partnerships with Spanish clinics or hospitals. Key risks include regulatory hurdles and adoption barriers in conservative healthcare systems. However, the growing telemedicine and AI diagnostics trends provide a tailwind. If D-Sight secures broader regulatory approvals and key clinical validations, it could capture a niche in the ophthalmology AI market, which is projected to reach several billion dollars by 2030. Near-term catalysts include potential CE mark renewals, clinical publications, and strategic collaborations.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) Clearance for Retinal Screening Software60% success
• Q3 2026Partnership with Major European Hospital Network70% success
• Q2 2026Publication of Pivotal Clinical Trial Results80% success